CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 137 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2014. The put-call ratio across all filers is 1.85 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $291,000 | +282.9% | 117,770 | +458.6% | 0.01% | +300.0% |
| Q1 2017 | $76,000 | -84.9% | 21,083 | -85.1% | 0.00% | -83.3% |
| Q4 2016 | $502,000 | +110.9% | 141,722 | +161.0% | 0.01% | +140.0% |
| Q2 2016 | $238,000 | +135.6% | 54,297 | +103.5% | 0.01% | +66.7% |
| Q1 2016 | $101,000 | -78.6% | 26,684 | -11.3% | 0.00% | -62.5% |
| Q4 2015 | $471,000 | -6.5% | 30,067 | -37.1% | 0.01% | 0.0% |
| Q3 2015 | $504,000 | -3.4% | 47,825 | +131.2% | 0.01% | -11.1% |
| Q2 2015 | $522,000 | +59.1% | 20,684 | +75.8% | 0.01% | +28.6% |
| Q1 2015 | $328,000 | -30.9% | 11,763 | -54.8% | 0.01% | -12.5% |
| Q4 2014 | $475,000 | +15.6% | 26,033 | -17.9% | 0.01% | 0.0% |
| Q3 2014 | $411,000 | +109.7% | 31,701 | +163.0% | 0.01% | +166.7% |
| Q2 2014 | $196,000 | -50.3% | 12,053 | -45.9% | 0.00% | -40.0% |
| Q1 2014 | $394,000 | -74.1% | 22,273 | -48.1% | 0.01% | -73.7% |
| Q3 2013 | $1,520,000 | – | 42,901 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TSP Capital Management Group, LLC | 813,273 | $3,286,000 | 1.66% |
| RTW INVESTMENTS, LP | 1,243,164 | $5,022,000 | 1.52% |
| Marcus Capital, LLC | 112,200 | $453,000 | 0.44% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 996,178 | $4,024,000 | 0.29% |
| Benchmark Capital Advisors | 67,000 | $271,000 | 0.20% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 360,299 | $1,456,000 | 0.20% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,907,523 | $11,746,000 | 0.15% |
| Virtus ETF Advisers LLC | 59,537 | $241,000 | 0.12% |
| Bellevue Group AG | 160,000 | $646,000 | 0.12% |
| PDT Partners, LLC | 428,300 | $1,730,000 | 0.10% |